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Introduction. Over the last years, significant weight 
gain in psychiatric patients also became an issue of 
increasing concern for medical community and society 
in general. It is a well-known adverse effect of several 
psychotropic medications, especially atypical (second-
generation) antipsychotics. Recent studies show that 
psychiatric patients, including patients with schizophrenia 
[1] and affective disorders [2, 3] are predisposed to 
weight gain as well as metabolic syndrome even without 
the exposure to psychotropic medications. The nature 
of this association is not completely understood. In 
addition to medications and genetic predisposition, many 
factors contribute to weigh gain and the development of 
metabolic syndrome in psychiatric patients, including low 
physical activity [4] and poor diet [5]. Therefore, health 
care providers have to be aware of weight gain and 
metabolic syndrome in these patents. 
Main text. Patients on antipsychotic medications 
frequently report increased appetite and “food craving”, 
and cardiometabolic side effects of antipsychotics 
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In this article are examined some of the key issues surrounding weight-gain in individuals suffering from mental 
disorders. It is showed that Weight gain is a common adverse effect of using anti-psychotic medications, and can 
be rapid and difficult to control. Weight gain does not seem to be dose dependent within the normal therapeutic 
range. The effect is worse with clozapine and olanzapine; minimal with aripiprazole and ziprasidone; and inter-
mediate with other antipsychotics, including low-potency First Generation Antipsychotics.
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У статті розглянуто ключові питання, пов’язані з коефіцієнтом збільшення маси тіла у людей, які 
страждають від психічних розладів. Показано, що збільшення маси є поширеним побічним ефектом 
використання антипсихотичних препаратів, що досить швидко розвивається і складно контролюється. 
Збільшення маси, ймовірно, залежить від середнього терапевтичного дозування препарату. Ефект 
найбільш виражений при застосуванні клозапіну й оланзапіну; мінімальний при застосуванні 
арипіпразолу і зипразидону; і займає проміжне місце, порівняно з іншими антипсихотичними 
препаратами, в тому числі з антипсихотиками першого покоління.
can be partially explained by increased appetite and 
weight gain. Histaminergic H1 and serotonergic 5HT-2C 
receptors play crucial role in regulating appetite. Those 
antipsychotics which block both these receptors, namely 
clozapine, olanzapine and quetiapine, cause the most 
significant weight gain [6]. In addition, the blocade of H1 
receptors is associated with sedation, which in turn can 
lead to weight gain due to inactivity. However, increased 
appetite and weight gain is not the only mechanism of the 
metabolic side effects of antipsychotics, and sometimes 
antipsychotics can cause diabetes even without obesity. 
Of note, second generation antipsychotics are associated 
with metabolic changes prior to changes in hunger, 
satiety, and food intake. This temporal separation 
suggests that there are differential mechanisms mediating 
antipsychotic-associated changes in metabolism and 
food intake [7]. One of the possible mechanisms is the 
blocade of the muscarinic M3 receptors of the pancreas, 
as antipsychotic agents with high binding affinity to these 
receptors are associated with an elevated risk for type 
2 diabetes [8]. 
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A total 36 patients with mental disorders were selected 
for the study. 18 men with average age 37 ± 7 years 
(range: 28-55 years) and 18 females with average age 37 
± 5 years (range: 31-51 years) were weighed and their 
height was measured. Additionally, we measured the 
waist circumference of the patients. The weighing and 
waist circumference measurement procedures were 
repeated three times monthly in October, November and 
December of 2015 - the period of the treatment with one 
of the following medications: risperidone, quetiapine, 
amilsulpride and olanzapine. Within the each sex group, 
patients were subjected to Risperidone, while Quetiapine, 
Amilsulpride and Zyprexa were prescribed to groups of 
three patients each. The control measurements were 
made before the beginning of the treatment.
Weight, height and Body mass index (BMI) were 
determined. BMI was computed as body weight (kg) 
divided by the square of height (m2). Nurses measured 
height and weight for each patient in the study group at 
the time of blood examination.
In order to investigate an effect of different medication, 
namely risperidone, quetiapine, amisulpride and zyprexa, 
used for the treatment of poly-etiological mental 
disorders on the  BMI, we studied 36 patients (18 females 
and 18 men), that were subjected to the treatment by 
one of the medications. Considering a described in 
the scientific literature effect of patient’s sex on the 
relationship between the studied parameters, females 
and men were analyzed separately. Thus, during three 
consecutive months of the treatment we examined a 
nine patients of the each sex subjected to risperidone, 
three patients of the each sex subjected to quetiapine, 
three patients of the each sex subjected to amilsupride, 
and three patients of the each sex subjected to zyprexa, 
monthly measuring their weight to BMI calculation. We 
also interviewed them in respect to their anthropometric 
parameters such as height and age. As the result we 
determined an average age of the selected group equal 
to 37 ages for both sexes (tab. 1).
Females Men
Risperidone 37.2 ± 7.3 37 ± 8.8
Quetiapine 37 ± 5.6 37 ± 2.6
Amisulpride 37.3 ±4.7 37 ± 6.1
Olanzapine 37.3 ± 2.1 37 ± 1.2
To investigate an effect of different second-generation 
antipsychotics (SGA) on the main parameters associated 
with the weight gain we first compared the control values 
of the patients later subjected to different SGA. The results 
displayed that all parameters in the control groups were 
very similar and these low alterations can be neglected 
for the analysis of the SGA medication effect.
The results demonstrated a consistent increase of 
the waist circumference in both groups of the males 
and females patients subjected to the treatment by 
risperidone, quetiapine, amisulpride and olanzapine 
compared to the control measurements (fig. 1, 2). Thus, 
after one month of the treatment with risperidone waist 
circumference reached ≈ 104% of the control for both 
males and females and continued to increase during the 
next two months of the treatment, reaching ≈ 108% of 
the control. Intriguingly, the similar trend of the effects 
of the risperidone, quetiapine and olanzapine on males 
and females was not observed for amisulpride. Thus, 
in females the waist circumference under amisulpride 
treatment grew to 105% of the control already in October 
and remained almost stable in November and December, 
Table 1. Average age ± StDev of the studied patients.
while in males the effect of amisulpride was weak after 
one months of the treatment and sharply increased in 
November and December reaching ≈ 109% of the control. 
Additionally should be noted that effect of quetiapine was 
slightly weaker compared to other tested SGA.
Body mass index (BMI) is one of parameter of the 
metabolic syndrome caused by SGA. We calculated BMI 
of the studied patients and the results revealed a time-
dependent step-wise increase of BMI under the treatment 
by the all used medications during three months period. 
Similarly to the waist circumference, increase of BMI 
under quetiapine treatment was the lowest (≈ 103-
107% of the control for both males and females) (fig. 
3, 4). Moreover, the effect of quetiapine specifically on 
males BMI was notable weaker compared to the other 
medications, reaching 104% of the control at the last 
month of the study. The strongest effect on BMI for both 
groups was observed for amisulpride treatment that 
caused increase up to 110% of the control. Our findings 
add more information to inconsistent evidences about 
amisulpride effect on BMI existed in the literature. Thus, 
majority of the studies reported about significant effect of 
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amisulpride on BMI increase [9, 10] that was also shown 
in this work. However, the authors also reported about 
Figure 1.  Effect of the tested SGA (see legend on the plot) on waist circumference in females.
Figure 3. Effect of the tested SGA on BMI in males.
Figure 2.  Effect of the tested SGA (see legend on the plot) on waist circumference in males.
more common use of amisulpride for the treatments of 
patients with high BMI. In our case the initial level of BMI 
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almost did not differ, but was the largest (insignificantly) 
for the group that was later subjected to quetiapine. Taken 
together, our results being in a row with the literature 
evidences that report high BMI of the patients subjected 
to amisulpride, do not show support observation of more 
preferably use of amilsulpride. On the other hand, our 
work argues with the evidences of the weaker effect of 
amisulpride on the weight gain [11].  Weight increases 
occurred in 7% of patients treated with amilsulpride for 
acute exacerbation of schizophrenia [12].
Recommended Monitoring Protocol
Prior to the initiation of SGA therapy, patients should 
be screened for diabetes, hypertension, dyslipidemia, and 
family history of cardiovascular disease. Weight, waist 
circumference should be encompassed in the screening. 
Ongoing monitoring should follow baseline-screening 
measures. Reassessment of all measures, except 
personal and family history and waist circumference, 
is recommended after 12 weeks of treatment for all 
patients treated with atypical antipsychotic medications. 
Thereafter, fasting plasma glucose, blood pressure, and 
waist circumference assessments should be completed 
annually and fasting lipid profile measured every 5 
years. Weight should be followed monthly for the first 
three months and quarterly thereafter. Ideally, obtain 
measurements monthly for the first 3 months of therapy, 
or after any medication adjustments, then at 6 months, 
and annually thereafter. Encourage patients to track 
Figure 4. Effect of the tested SGA on BMI in females.
their own weight.  Obtain another set of measurements 
at 3 months, then annually thereafter, unless the patient 
develops type 2 diabetes mellitus [13].
Conclusion. Atypical antipsychotics are used 
extensively for Food and Drugs Administration-approved 
indications including schizophrenia and, more recently, 
bipolar mania. These agents are considered first-line 
treatments and have significant advantages over 
the typical antipsychotics due to their lower risk of 
extrapyramidal side effects and their beneficial effects 
on negative symptoms, cognition, and mood. Recent 
reports on weight gain, new-onset type 2 diabetes, 
and dyslipidemia require patients to receive ongoing 
monitoring for these conditions. 
Although certain atypical antipsychotics, such as 
olanzapine and clozapine, have been associated with the 
greatest weight gain and the highest risk of diabetes and 
dyslipidemia, not all patients taking these agents gain a 
significant amount of weight.
Although there are differences in potential weight 
gain and, consequently, dyslipidemia among the atypical 
antipsychotics, differences in risk for diabetes are not as 
easily quantifiable. This may be due in part to the uncertain 
etiology of these metabolic abnormalities, but overall their 
prevalence seems to correlate with weight gain. 
Risperidone and quetiapine have been shown to have 
intermediate effects, while ziprasidone and aripiprazole 
are reported with little or no significant weight gain.
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